NO20054087L - Preparater omfattende fotalt hemoglobin og bakterielt endotoksin og eventuelt ytterligere fotale leverkomponenter - Google Patents

Preparater omfattende fotalt hemoglobin og bakterielt endotoksin og eventuelt ytterligere fotale leverkomponenter

Info

Publication number
NO20054087L
NO20054087L NO20054087A NO20054087A NO20054087L NO 20054087 L NO20054087 L NO 20054087L NO 20054087 A NO20054087 A NO 20054087A NO 20054087 A NO20054087 A NO 20054087A NO 20054087 L NO20054087 L NO 20054087L
Authority
NO
Norway
Prior art keywords
hemoglobin
photal
endotoxin
surprisingly
biomedical
Prior art date
Application number
NO20054087A
Other languages
English (en)
Other versions
NO20054087D0 (no
NO334003B1 (no
Inventor
Antonio Verdini
Otto Westphal
Thierry Walli
Reginald Gorczynski
Silke Mueller
Jean-Pierre Mach
Wolfgang Bessler
Petra Hofmann
Ulrich Zahringer
Christian Alexander
Ulrich Vor Dem Esche
Artur J Ulmer
Original Assignee
Clinique La Prairie Res Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinique La Prairie Res Sa filed Critical Clinique La Prairie Res Sa
Publication of NO20054087D0 publication Critical patent/NO20054087D0/no
Publication of NO20054087L publication Critical patent/NO20054087L/no
Publication of NO334003B1 publication Critical patent/NO334003B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelse vedrører et farmasøytisk preparat som representerer et nyskapende immunmodulatorisk prinsipp som omfatter bakterielt endottoksin, føtalt hemoglobin eller nærmere bestemt et hemfritt derivat eller y-kjeden derav, og valgfritt, komponenter som foreligger i den føtale lever i tillegg til HbF. Preparatet leveres til mennesker i en farmasøytisk akseptabel bærer og/eller et farmasøytisk akseptabelt fortynningsmiddel. I samsvar med den foreliggende oppfinnelse ble det overraskende funnet at endotoksin og føtalt hemoglobins delstrukturer fremviser en uttalt synergistisk biomedisinsk aktivitet. Den biomedisinske virkning av føtalt hemoglobin og dets delstrukturer er overraskende ikke basert på en klassisk hemoglobinfunksjon som en oksygentransportør, men relatert til en modulering av endotoksinformidlet bioaktivitet. Den biomedisinske aktivitet blir overraskende også observert etter oral tilførsel av preparatet. Preparatet ifølge oppfinnelsen finner et utvalg av anvendelser som har til felles stimuleringen av immunsystemet og reverseringen i polarisasjon av cytokiner og kemokiner fra en Th2-rettet respons til en Th1 -typerespons. De foreslåtte anvendelser ville derfor inkludere behandlingen av allergiske tilstander, ondartetheter, kroniske infeksjoner, autoimmunfenomener og aldersrelaterte ubalanser.
NO20054087A 2003-02-18 2005-09-02 Farmasøytisk preparat omfattende ikke-humant føtalt hemoglobin og bakterielt endotoksin, samt anvendelsen av dette NO334003B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003687A EP1449535B1 (en) 2003-02-18 2003-02-18 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components
PCT/EP2004/001553 WO2004073728A2 (en) 2003-02-18 2004-02-18 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components

Publications (3)

Publication Number Publication Date
NO20054087D0 NO20054087D0 (no) 2005-09-02
NO20054087L true NO20054087L (no) 2005-11-08
NO334003B1 NO334003B1 (no) 2013-11-11

Family

ID=32731533

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054087A NO334003B1 (no) 2003-02-18 2005-09-02 Farmasøytisk preparat omfattende ikke-humant føtalt hemoglobin og bakterielt endotoksin, samt anvendelsen av dette

Country Status (20)

Country Link
US (1) US7968103B2 (no)
EP (2) EP1449535B1 (no)
JP (1) JP4619352B2 (no)
KR (1) KR101102481B1 (no)
CN (1) CN1750840A (no)
AT (1) ATE324903T1 (no)
AU (1) AU2004212703C1 (no)
BR (1) BRPI0407311B8 (no)
CA (1) CA2514485C (no)
DE (1) DE60304989T2 (no)
DK (1) DK1449535T3 (no)
ES (1) ES2263859T3 (no)
IL (1) IL169760A (no)
IS (1) IS2294B (no)
MX (1) MXPA05008797A (no)
NO (1) NO334003B1 (no)
NZ (1) NZ541417A (no)
PL (1) PL211789B1 (no)
RU (1) RU2366449C2 (no)
WO (1) WO2004073728A2 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080070971A1 (en) * 2006-03-06 2008-03-20 Wang Xiang H Medical Use of Bilirubin and its Structural Analogues
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2010006200A2 (en) * 2008-07-09 2010-01-14 Board Of Regents, The University Of Texas System Triggered release of drugs from polymer particles
AU2010239463B2 (en) 2009-04-20 2016-12-08 Galenbio, Inc. Compositions for transfection of biomolecules into cells
EP2789343A1 (en) * 2013-04-11 2014-10-15 Clinique La Prairie Novel hemoglobin-derived peptide based pharmaceutical compositions
EP3019186A4 (en) * 2013-07-12 2017-03-29 Patrick J. Casey Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473647A (en) * 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
WO1987006830A1 (en) 1986-05-09 1987-11-19 Sloan-Kettering Institute For Cancer Research Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment
DE69021791T2 (de) 1989-06-30 1996-05-02 American Cyanamid Co Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen.
JPH0690745A (ja) * 1990-08-20 1994-04-05 Chiba Seifun Kk Ｌｐｓ産生菌、ｌｐｓ、ｌｐｓを含む医薬及び動物薬
CA2049548C (en) 1990-08-20 2002-07-02 Kiyoshi Yoshimura Lps-producing bacteria, lpss, and lps-containing medicines and veterinary medicines
JPH0499481A (ja) * 1990-08-20 1992-03-31 Chiba Seifun Kk 新規細菌、新規ｌｐｓ、新規免疫機能活性化剤、新規動物用免疫機能活性化剤
JPH04187640A (ja) * 1990-11-22 1992-07-06 Chiba Seifun Kk 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤
EP0539610A1 (en) * 1991-10-26 1993-05-05 Torf Establishment Method and composition for determining the immunological activity of solutions containing active substances
JP3199081B2 (ja) * 1992-11-13 2001-08-13 味の素株式会社 抗腫瘍剤
DE4338812A1 (de) * 1993-11-15 1995-05-18 Braun Melsungen Ag Verwendung von Lösungen von vernetztem Hämoglobin zur Bekämpfung des septischen und hämorrhagischen Schocks bei Säugetieren
US5648343A (en) 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US5580724A (en) * 1994-03-25 1996-12-03 Board Of Regents, The University Of Texas System Differential expansion of fetal stem cells in maternal circulation for use in prenatal genetic analysis
US20020065211A1 (en) * 1995-03-23 2002-05-30 Biopure Corporation Increasing function of organs having reduced red blood cell flow
ATE200893T1 (de) * 1995-10-06 2001-05-15 Vertex Pharma Butyrat-medikamentvorstufen der milchsäure
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
EP0856592A1 (en) 1997-02-04 1998-08-05 N.V. Bekaert S.A. A coating comprising layers of diamond like carbon and diamond like nanocomposite compositions
US6228471B1 (en) * 1997-02-04 2001-05-08 N.V. Bekaert S.A. Coating comprising layers of diamond like carbon and diamond like nanocomposite compositions
RU2140283C1 (ru) * 1998-12-15 1999-10-27 Товарищество с ограниченной ответственностью "Биотех" Фармацевтический препарат на основе интерлейкина-2 (варианты)
JP5099951B2 (ja) * 1999-11-12 2012-12-19 バクスター・インターナショナル・インコーポレイテッド 副作用が減少されたヘモグロビン組成物
PT2295968E (pt) * 1999-12-03 2013-01-09 Baxter Int Teste de pirogenicidade para utilização com sistemas automatizados de imunoensaio
AU783099B2 (en) * 2000-01-07 2005-09-22 Rohm Gmbh & Co. Kg Selective activation of a TH1 or TH2 lymphocyte regulated immune response
WO2002017965A1 (en) * 2000-08-28 2002-03-07 Akira Awaya Medicinal compositions
DE10103211C1 (de) * 2001-01-24 2002-07-18 Ursula Kastner Kulturmedium

Also Published As

Publication number Publication date
EP1449535B1 (en) 2006-05-03
PL378573A1 (pl) 2006-05-02
MXPA05008797A (es) 2006-05-25
IS7940A (is) 2005-07-18
EP1449535A1 (en) 2004-08-25
DE60304989T2 (de) 2007-03-29
CN1750840A (zh) 2006-03-22
JP2006518350A (ja) 2006-08-10
NO20054087D0 (no) 2005-09-02
RU2005126141A (ru) 2006-01-27
CA2514485A1 (en) 2004-09-02
IL169760A (en) 2012-09-24
PL211789B1 (pl) 2012-06-29
AU2004212703B2 (en) 2008-10-30
CA2514485C (en) 2013-11-05
WO2004073728A2 (en) 2004-09-02
BRPI0407311B1 (pt) 2020-12-29
NO334003B1 (no) 2013-11-11
EP1601371A2 (en) 2005-12-07
KR20050111596A (ko) 2005-11-25
AU2004212703C1 (en) 2009-05-21
BRPI0407311B8 (pt) 2021-11-30
KR101102481B1 (ko) 2012-01-05
AU2004212703A1 (en) 2004-09-02
RU2366449C2 (ru) 2009-09-10
ATE324903T1 (de) 2006-06-15
WO2004073728A3 (en) 2004-10-07
DE60304989D1 (de) 2006-06-08
DK1449535T3 (da) 2006-09-11
BRPI0407311A (pt) 2006-02-21
ES2263859T3 (es) 2006-12-16
IS2294B (is) 2007-10-15
US7968103B2 (en) 2011-06-28
US20080075742A1 (en) 2008-03-27
JP4619352B2 (ja) 2011-01-26
NZ541417A (en) 2008-08-29

Similar Documents

Publication Publication Date Title
EP2343308A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
WO2009039981A3 (en) Use of (arg 8) vasopressin to treat eg s. pneumoniae infection
DK1599227T3 (da) Fremgangsmåder til immunmodulation hos dyr
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
NO20052739L (no) CCR5-antagonister som medikamenter
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
RU94046424A (ru) Способ разделения форм днказы, днказа человека, фармацевтическая композиция, способ хранения днказы, способ лечения
BG101118A (en) Therapeutical compounds
IL157327A (en) Use of n-acetylglucosamine polymers for the preparation of medicaments for modulation of vascular structure and/or function
WO2007106617A3 (en) Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
EP2305269A3 (en) Immunemodulating oligosaccharides
DK1057828T3 (da) Orale trovafloxacin-suspensioner
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2004073728A3 (en) Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
WO2000072833A3 (de) Pharmazeutische zubereitungen zur hemmung von spimgomyelinase
WO2005091937A3 (en) Compositions useful for the treatment of microbial infections
WO2003039437A3 (de) Oral verabreichbare pharmazeutische zubereitung umfassend liposo mal verkapseltes taxol
RU96120655A (ru) Композиция для профилактики и лечения гриппа и орви
WO2008049881A3 (en) Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
WO2023092090A8 (en) Immunogenic fusion protein compositions and methods of use thereof
ATE369145T1 (de) Aus einer bifidobakterien-kultur gewonnener immunomodulator und diesen enthaltende zusammensetzungen
DE602004025103D1 (de) Heilkräuterzusammensetzung zur Behandlung von AIDS
WO2024233382A3 (en) Methods for using bacteria and host/microbiota-derived metabolites for diagnosis and treatment of endometriosis
DE69902925D1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CLINIQUE LA PRAIRIE FRANCHISING SA, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CLINIQUE LA PRAIRIE FRANCHISING SA, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: CLINIQUE LA PRAIRIE S.A., CH